Q/C Technologies, Inc. (QCLS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Q/C Technologies, Inc. (QCLS) has a cash flow conversion efficiency ratio of -0.139x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.29 Million) by net assets ($23.69 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Q/C Technologies, Inc.'s balance sheet to measure how much of total assets are equity-financed.
Q/C Technologies, Inc. - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Q/C Technologies, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore QCLS strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Q/C Technologies, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Q/C Technologies, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Resintech Bhd
KLSE:7232
|
0.070x |
|
Calgro M3 Holdings Ltd
JSE:CGR
|
-0.059x |
|
Riverside Resources Inc
V:RRI
|
-0.062x |
|
Israel Op L
TA:ISOP
|
0.000x |
|
SUNDRAGON S.A. ZY-1
F:6EI
|
-0.247x |
|
Alumexx N.V.
AS:ALX
|
0.082x |
|
Mirae ING Co Ltd
KO:007120
|
0.028x |
|
Matritense Real Estate SOCIMI S.A.
MC:YMAT
|
-0.108x |
Annual Cash Flow Conversion Efficiency for Q/C Technologies, Inc. (2020–2025)
The table below shows the annual cash flow conversion efficiency of Q/C Technologies, Inc. from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see QCLS market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $21.75 Million | $-9.07 Million | -0.417x | +31.66% |
| 2024-12-31 | $14.72 Million | $-8.98 Million | -0.610x | +39.99% |
| 2023-12-31 | $12.77 Million | $-12.98 Million | -1.016x | -21.70% |
| 2022-12-31 | $14.70 Million | $-12.27 Million | -0.835x | -1.17% |
| 2021-12-31 | $23.65 Million | $-19.52 Million | -0.825x | -136.38% |
| 2020-12-31 | $-5.26 Million | $-11.92 Million | 2.268x | -- |
About Q/C Technologies, Inc.
Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company. It operates through Pharmaceuticals and Computing Technology segments. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, … Read more